14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ENTA ranks #17697 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Enanta Pharmaceuticals Stock Forecast NASDAQ:ENTA

$56.49 (-1.05%)

Volume: 226k

Closed: Jan 21, 2022

Hollow Logo Score: -4.922

Enanta Pharmaceuticals Stock Forecast

$56.49 (-1.05%)

Volume: 226k

Closed: Jan 21, 2022

Score Hollow Logo -4.922

Enanta Pharmaceuticals Company Profile

500 Arsenal Street

Watertown MA 02472

617-607-0800

www.enanta.com

Industry: Biotechnology

Sector: Healthcare

Enanta Pharmaceuticals

Description

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company’s research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease inhibitor designed for use against HCV. The company also develops HCV protease inhibitor in phase III development with AbbVie, as well as a HCV program using a different class of molecules known as cyclophilin inhibitors. In addition, it has a program in non-alcoholic steatohepatitis; and discovers programs in other areas of viral infection and liver disease. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE